U.S. District Court rules in favor of Lilly's Alimta patent

June 22 (Reuters) - Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India's Dr. Reddy's Laboratories from launching generics until the patent expires.